#China #Shanghai #Autoimmune Disease #Antengene #ATG-201

Antengene Achieves Significant Development Milestone with IND Approval for ATG-201

In a groundbreaking announcement, Antengene Corporation Limited, recognized as a leader in biotechnology, has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) for ATG-201. This innovative drug is a CD19/CD3 bispecific T-cell engager antibody, aimed at treating B cell-related autoimmune diseases. This commendable accomplishment marks a critical point in Antengene's evolution as it expands its focus to autoimmune diseases, alongside its established interests in oncology and hematology.

Understanding ATG-201

The design of ATG-201 incorporates steric hindrance masking technology, enabling it to effectively target and eliminate CD19-expressing B cells. This plays a crucial role in managing diseases driven by B cells by harnessing the power of the body's immune system. ATG-201 represents a promising solution for conditions that currently have limited treatment options.

Phase I ATTRACT Study

The Phase I study, known as ATTRACT, will be led by Professor Zhanguo Li from Peking University People's Hospital. This study is structured to assess both the safety and efficacy of ATG-201 in adult patients suffering from autoimmune diseases related to B cells. It will be conducted in two parts: dose escalation and dose expansion. The primary goal is to ascertain the safety and tolerability of ATG-201, while secondary objectives will evaluate pharmacokinetic (PK) and pharmacodynamic (PD) profiles, among others.

Professor Li expressed his enthusiasm about leading this first-in-human trial, emphasizing the significant unmet needs in treating refractory B cell-mediated autoimmune diseases. ATG-201 could potentially provide a much-needed therapeutic option for patients facing low remission and high relapse rates.

Strategic Collaboration with UCB

Antengene has formed a partnership with UCB, granting them an exclusive global license for the development, manufacturing, and commercialization of ATG-201. While Antengene will handle the initial clinical trials in China and Australia, UCB will take over further development activities after these trials. This collaboration is indicative of the confidence in ATG-201 and its potential impact on patients' lives.

Forward Momentum for Antengene

The approval of ATG-201's clinical trial application is a testament to Antengene's innovative vision and its commitment to addressing significant unmet medical needs in the autoimmune disease arena. This move illustrates the company's proactive strategy to diversify its therapeutic focus, ensuring they remain at the forefront of biotech advancements.

As Antengene shifts its focus towards autoimmune diseases, it stands poised to make significant contributions that may redefine treatment methodologies in a field characterized by a lack of effective solutions. The ultimate goal remains clear: to develop transformative therapies that provide real hope to patients worldwide.

Conclusion

With a robust pipeline of candidates and the introduction of ATG-201, Antengene is well on its way to reshaping the landscape of autoimmune disease treatments. Their commitment to research and dedication to addressing complex medical challenges reflect a bright future for innovative therapeutic solutions.

About Antengene Corporation

Antengene Corporation Limited is a globally driven organization focused on developing groundbreaking therapeutics for diseases with considerable unmet medical needs. The company has a diverse pipeline of investigational medications, including various CD19-engaging programs and other first-in-class candidates. With a strong operational base and continuous dedication to research, Antengene is uniquely positioned to tackle the challenges within the healthcare sector.